Syneron Bio

The firm's core technology is its proprietary Synova™ platform, an intelligent, high-throughput system for macrocyclic peptide drug discovery and development. This platform combines the beneficial attributes of small-molecule drugs and larger biologic therapies, aiming to create treatments with high potency and specificity for difficult-to-drug targets. Syneron Bio has also developed SynCore, a generative AI design platform for synthetic peptide drugs.

The company's business model centers on leveraging its platform to build a pipeline of drug candidates targeting oncology and chronic diseases, including rare, autoimmune, and metabolic conditions. Syneron Bio generates revenue through strategic collaborations with large pharmaceutical companies. A significant partnership with AstraZeneca involves upfront payments, potential near-term milestone payments of $75 million, and up to $3.4 billion in additional development and commercial milestones, plus tiered royalties on global sales. This collaboration grants AstraZeneca access to the Synova™ platform to advance research programs.

Within three years of its founding, Syneron Bio has raised nearly $100 million in Series A and A+ financing rounds. Key investors include AstraZeneca, AZ-CICC Healthcare Investment Fund, Pfizer Biotech Development Investment Fund, GL Ventures, 5Y Capital, Sinovation Ventures, and Lenovo Capital. This capital is intended to enhance the Synova™ platform and advance multiple drug pipelines toward clinical stages.